ALLARITY THERAPEUTICS INC (ALLR) Fundamental Analysis & Valuation

NASDAQ:ALLR • US0167445008

Current stock price

1.16 USD
+0.03 (+2.65%)
Last:

This ALLR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ALLR Profitability Analysis

1.1 Basic Checks

  • In the past year ALLR has reported negative net income.
  • In the past year ALLR has reported a negative cash flow from operations.
  • In the past 5 years ALLR always reported negative net income.
  • ALLR had a negative operating cash flow in each of the past 5 years.
ALLR Yearly Net Income VS EBIT VS OCF VS FCFALLR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • ALLR's Return On Assets of -73.62% is on the low side compared to the rest of the industry. ALLR is outperformed by 65.18% of its industry peers.
  • ALLR has a Return On Equity (-127.47%) which is in line with its industry peers.
Industry RankSector Rank
ROA -73.62%
ROE -127.47%
ROIC N/A
ROA(3y)-142.64%
ROA(5y)-100.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALLR Yearly ROA, ROE, ROICALLR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

  • ALLR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALLR Yearly Profit, Operating, Gross MarginsALLR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ALLR Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ALLR has been increased compared to 1 year ago.
  • The number of shares outstanding for ALLR has been increased compared to 5 years ago.
  • ALLR has a better debt/assets ratio than last year.
ALLR Yearly Shares OutstandingALLR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M
ALLR Yearly Total Debt VS Total AssetsALLR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • ALLR has an Altman-Z score of -9.32. This is a bad value and indicates that ALLR is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -9.32, ALLR is doing worse than 71.95% of the companies in the same industry.
  • There is no outstanding debt for ALLR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.32
ROIC/WACCN/A
WACCN/A
ALLR Yearly LT Debt VS Equity VS FCFALLR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • ALLR has a Current Ratio of 2.33. This indicates that ALLR is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.33, ALLR is doing worse than 72.92% of the companies in the same industry.
  • A Quick Ratio of 2.33 indicates that ALLR has no problem at all paying its short term obligations.
  • ALLR's Quick ratio of 2.33 is on the low side compared to the rest of the industry. ALLR is outperformed by 70.21% of its industry peers.
Industry RankSector Rank
Current Ratio 2.33
Quick Ratio 2.33
ALLR Yearly Current Assets VS Current LiabilitesALLR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ALLR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 94.23% over the past year.
EPS 1Y (TTM)94.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 18.82% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y98.99%
EPS Next 2Y40.98%
EPS Next 3Y18.82%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALLR Yearly Revenue VS EstimatesALLR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2027 2M 4M 6M 8M
ALLR Yearly EPS VS EstimatesALLR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -500K -1M -1.5M

More info and screens

Find the best growth stocksShow best growing peers

0

4. ALLR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALLR. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALLR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALLR Price Earnings VS Forward Price EarningsALLR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALLR Per share dataALLR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALLR's earnings are expected to grow with 18.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.98%
EPS Next 3Y18.82%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALLR Dividend Analysis

5.1 Amount

  • No dividends for ALLR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALLR Fundamentals: All Metrics, Ratios and Statistics

ALLARITY THERAPEUTICS INC

NASDAQ:ALLR (4/2/2026, 8:07:45 PM)

1.16

+0.03 (+2.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31
Earnings (Next)05-09
Inst Owners8.04%
Inst Owner Change25.06%
Ins Owners0.98%
Ins Owner Change2.72%
Market Cap18.65M
Revenue(TTM)N/A
Net Income(TTM)-15.31M
Analysts82.86
Price Target9.69 (735.34%)
Short Float %1.82%
Short Ratio1.61
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.49%
Min EPS beat(2)19.01%
Max EPS beat(2)29.97%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.7%
PT rev (3m)5.56%
EPS NQ rev (1m)4.35%
EPS NQ rev (3m)-4.76%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.55
P/tB 1.55
EV/EBITDA N/A
EPS(TTM)-2.31
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0
BVpS0.75
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -73.62%
ROE -127.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-142.64%
ROA(5y)-100.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.33
Quick Ratio 2.33
Altman-Z -9.32
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.54%
EPS Next Y98.99%
EPS Next 2Y40.98%
EPS Next 3Y18.82%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.35%
OCF growth 3YN/A
OCF growth 5YN/A

ALLARITY THERAPEUTICS INC / ALLR Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ALLARITY THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to ALLR.


What is the valuation status of ALLARITY THERAPEUTICS INC (ALLR) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALLARITY THERAPEUTICS INC (ALLR). This can be considered as Overvalued.


How profitable is ALLARITY THERAPEUTICS INC (ALLR) stock?

ALLARITY THERAPEUTICS INC (ALLR) has a profitability rating of 0 / 10.


What is the expected EPS growth for ALLARITY THERAPEUTICS INC (ALLR) stock?

The Earnings per Share (EPS) of ALLARITY THERAPEUTICS INC (ALLR) is expected to grow by 98.99% in the next year.